<!DOCTYPE html>
<html lang="zh">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <meta name="author" content="Health Pulse">
  <title>Oral GLP - 1 Drug War: Who Can Overturn the Dominance of 'Weight - Loss Injections'? - Health Pulse - PeacLove Top Insigths </title>
  <meta name="keywords" content="oral GLP - 1 drugs, weight loss, Semaglutide, GLP - 1 receptor agonists" />
  <meta name="description" content="The battle of oral GLP - 1 receptor agonists is heating up. This article explores the background, players, challenges, and future trends of these drugs in the weight - loss market." />
  <link rel="stylesheet" href="style.css" />
  <script src="getdata.js" defer></script>
</head>
<body>

  <!-- é¢åŒ…å±‘å¯¼èˆª -->
  <ol class="breadcrumb">
    <li><a href="/">Home</a></li>
    <li>-</li>
    <li><a href="index.html">Health Pulse</a></li>
    <li>-</li>
    <li id="breadcrumb-title">Oral GLP - 1 Drug War: Who Can Overturn the Dominance of 'Weight - Loss Injections'?</li>
	<div style="clear:both"></div>
  </ol>

  <main>
    <h2 id="article-title">Oral GLP - 1 Drug War: Who Can Overturn the Dominance of 'Weight - Loss Injections'?</h2>
    <p id="article-date" class="article-date">PeaceLove.Top Insights :2025-04-12</p>
    <img id="article-image" src="images/34.png" alt="Oral GLP - 1 Drug War: Who Can Overturn the Dominance of 'Weight - Loss Injections'?" loading="lazy" />
    <div id="article-description"><h3>ğŸ¯ Introduction</h3><p>Hello! ğŸ‘‹ I'm your health detective. ğŸ” Today, let's talk about a quiet but far - reaching pharmaceutical revolution: the battle of oral GLP - 1 receptor agonists! If you've ever thought: 'I wish I could lose weight without getting injections...' or 'Weight - loss injections are too expensive and hard to get. Is there an oral version?' Then you really need to get to know Novo Nordisk's oral Semaglutide!</p><h3>ğŸ’Š Self - Introduction</h3><p>I'm an ordinary person who is terrified of injections but loves cakes. ğŸ°ğŸ’‰ When I heard about a 'weight - loss injection you can swallow', I immediately started researching. ğŸ“š</p><h3>ğŸš€ Background: The Weight - Loss Myth of GLP - 1 Drugs</h3><p>In the past few years, 'GLP - 1 receptor agonists' have become the hottest anti - obesity drug category globally:</p><table><tr><th>Drug Name</th><th>Form</th><th>Brand</th><th>Weight - Loss Effect</th></tr><tr><td>Ozempic</td><td>Injection</td><td>Novo Nordisk</td><td>~15%</td></tr><tr><td>Wegovy</td><td>Injection</td><td>Novo Nordisk</td><td>~15%</td></tr><tr><td>Mounjaro (Tirzepatide)</td><td>Injection</td><td>Eli Lilly</td><td>~21%</td></tr><tr><td>Oral Semaglutide</td><td>ğŸ’Š Oral</td><td>Novo Nordisk</td><td>ğŸ“ˆ Comparable to injections!</td></tr></table><h3>ğŸ’¥ Case Highlight: Novo Nordisk's Oral Semaglutide Debuts Strongly!</h3><p>ğŸ“Œ Drug name: Rybelsus. ğŸ’Š Specifications: 3mg / 7mg / 14mg. ğŸ“Š In the 2023 OASIS 1 trial, a 50mg oral dose of Semaglutide achieved an average weight loss of 15.1%, almost matching the injection version of Wegovy! This is not just a simple 'conversion to a capsule'. Novo Nordisk added an absorption enhancer (SNAC) to enable Semaglutide, a large - molecule drug that is difficult to absorb, to be effectively absorbed in the stomach. This breakthrough is hailed as:</p><p>ğŸ‰ 'A milestone in large - molecule oral drugs'</p><h3>ğŸ”¥ The Market Is Booming, and the Oral Version Becomes the New Main Battlefield in the GLP - 1 War!</h3><p>Why do people want to develop oral versions?</p><ol><li>ğŸ’‰ Say goodbye to the fear of injections.</li><li>ğŸ’Š Higher convenience in taking the medicine.</li><li>âœ… Improved compliance and greater user stickiness.</li><li>ğŸ’° Expected to reduce pharmaceutical and distribution costs (injection drugs require cold storage and professional operation).</li></ol><h3>ğŸ¥Š Who Are the Players in the Oral GLP - 1 Track?</h3><table><tr><th>Pharmaceutical Company</th><th>Product Name</th><th>Status</th></tr><tr><td>Novo Nordisk</td><td>Rybelsus (Semaglutide)</td><td>Launched (for diabetes) / 50mg weight - loss version in clinical trials</td></tr><tr><td>Pfizer</td><td>Danuglipron</td><td>Phase II clinical trials, not yet widely used</td></tr><tr><td>Eli Lilly</td><td>Orforglipron</td><td>Phase III in progress, regarded as the'strongest competitor'</td></tr><tr><td>vTv Therapeutics</td><td>TTP399</td><td>In the early stage of research and development</td></tr></table><h3>âš ï¸ Challenges and Controversies: Oral Drugs Aren't All Advantages</h3><p>Although the oral version 'seems great', there are also many technical and usage thresholds:</p><ul><li>ğŸš§ Strict medication rules. â— Rybelsus requires taking it on an empty stomach, in the morning, with water, and not eating or drinking for 30 minutes after taking it. â— The onset of the drug effect is slower than that of injections. â— Although SNAC improves absorption, it also causes gastric irritation and increases side effects.</li><li>ğŸ’Š The cost has not significantly decreased. Due to the complex production process and high dosage, the actual price is not very different from that of injections (in the short term).</li></ul><h3>ğŸ§  Future Scientific Trends: More Potent and Intelligent Oral Drugs</h3><p>ğŸŒ± The scientific community is currently exploring:</p><ul><li>ğŸ“¦ Nanoparticle delivery systems (to enhance stability).</li><li>ğŸ§¬ RNA/protein modification to extend the half - life.</li><li>ğŸ¤– AI - assisted discovery of more efficient receptor agonists.</li></ul><h3>ğŸ“Œ Summary</h3><p>The oral version is not a replacement but an expansion of choices. âœ… It is more friendly to those who are afraid of injections and for early intervention. âœ… It is more beneficial for chronic disease management and global market promotion. âœ… For end - users, it provides one more choice and less anxiety. Although oral GLP - 1 drugs cannot completely replace injections at present, they are quietly changing the entire landscape of weight - loss treatment. ğŸŒ In the future, perhaps all you need to start losing weight is a small pill. ğŸ’Š</p></div>

    <!-- ä¸‹ä¸€ç¯‡æ¨è -->
    <section id="next-article-section" style="display: none;">
      <h3>ä¸‹ä¸€ç¯‡æ¨è</h3>
      <a id="next-article-link">
        <img id="next-article-image" alt="ä¸‹ä¸€ç¯‡">
        <h4 id="next-article-title"></h4>
      </a>
    </section>

    <!-- çŒœä½ å–œæ¬¢ -->
    <section>
      <h3>çŒœä½ å–œæ¬¢</h3>
      <ul id="related-articles"></ul>
    </section>
  </main>
  
  <!-- æµ®åŠ¨æŒ‰é’®å®¹å™¨ -->
<div class="floating-buttons">
  <a href="index.html" class="float-btn home-btn" title="è¿”å›é¦–é¡µ">Home</a>
  <button id="scrollToTop" class="float-btn top-btn" title="è¿”å›é¡¶éƒ¨">Top</button>
</div>

</body>
</html>
